Oramed Pharmaceuticals (ORMP) Equity Average (2022 - 2025)
Oramed Pharmaceuticals' Equity Average history spans 4 years, with the latest figure at $201.0 million for Q4 2025.
- For Q4 2025, Equity Average changed N/A year-over-year to $201.0 million; the TTM value through Dec 2025 reached $201.0 million, changed N/A, while the annual FY2023 figure was $157.0 million, N/A changed from the prior year.
- Equity Average reached $201.0 million in Q4 2025 per ORMP's latest filing, up from $178.0 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $201.0 million in Q4 2025 to a low of $146.7 million in Q2 2025.
- Average Equity Average over 4 years is $160.2 million, with a median of $154.3 million recorded in 2022.
- Peak YoY movement for Equity Average: grew 13.65% in 2024, then fell 14.16% in 2025.
- A 4-year view of Equity Average shows it stood at $152.2 million in 2022, then rose by 2.24% to $155.6 million in 2023, then increased by 6.61% to $165.8 million in 2024, then grew by 21.22% to $201.0 million in 2025.
- Per Business Quant, the three most recent readings for ORMP's Equity Average are $201.0 million (Q4 2025), $178.0 million (Q3 2025), and $146.7 million (Q2 2025).